1 00:00:06,200 --> 00:00:08,959 Speaker 1: Welcome to the Fear and Greed Business Interview. I'm Sean Almer. 2 00:00:09,080 --> 00:00:12,280 Speaker 1: The pandemic reminded the world of the importance of vaccines 3 00:00:12,360 --> 00:00:16,120 Speaker 1: and demonstrated the extraordinary ability of health professionals to innovate. 4 00:00:16,760 --> 00:00:20,720 Speaker 1: The latest developments in medical technology are another giant leap forward. 5 00:00:21,079 --> 00:00:24,439 Speaker 1: Needle free vaccines might sound a little bit like science fiction, 6 00:00:24,800 --> 00:00:27,880 Speaker 1: but clinical trials have shown it's not just possible, but 7 00:00:27,920 --> 00:00:31,000 Speaker 1: it can improve the effectiveness of a vaccine immune response. 8 00:00:31,320 --> 00:00:34,120 Speaker 1: My guest today is David Howey, the President and CEO 9 00:00:34,200 --> 00:00:37,720 Speaker 1: of Vaxis, the company behind this needle free technology. Vaxis 10 00:00:37,760 --> 00:00:41,320 Speaker 1: works across the US and Australia, developing and commercializing its 11 00:00:41,360 --> 00:00:44,080 Speaker 1: products in Brisbane. The Brisbane health sector is the fastest 12 00:00:44,080 --> 00:00:47,280 Speaker 1: growing in Australia and in medical and pharmaceutical products. Growth 13 00:00:47,280 --> 00:00:50,360 Speaker 1: in Brisbane has occurred seven times faster than the rest 14 00:00:50,400 --> 00:00:53,559 Speaker 1: of Australia. Companies in this space are benefiting from commercial 15 00:00:53,600 --> 00:00:57,640 Speaker 1: and research partnerships as well as the Medtech Accelerated Program, 16 00:00:57,680 --> 00:01:01,160 Speaker 1: an initiative of the Brisbane Economic Development Agency, a great 17 00:01:01,160 --> 00:01:03,560 Speaker 1: supporter of this podcast. As I mentioned, I'm joined today 18 00:01:03,560 --> 00:01:06,880 Speaker 1: by David Howey, the President and CEO of Access David, 19 00:01:06,880 --> 00:01:07,840 Speaker 1: Welcome to Fear and Greed. 20 00:01:08,080 --> 00:01:09,319 Speaker 2: Thank you, it's great to be here. 21 00:01:09,920 --> 00:01:13,360 Speaker 1: Let's start at the very beginning. Tell me about the technology. 22 00:01:13,480 --> 00:01:14,240 Speaker 1: How does it work? 23 00:01:14,880 --> 00:01:18,039 Speaker 2: So well? The technology has its origins at the University 24 00:01:18,080 --> 00:01:22,760 Speaker 2: of Queensland at the Australian Institute for Biotechnology and now Engineering, 25 00:01:23,080 --> 00:01:26,320 Speaker 2: and VA's has actually formed in twenty eleven licensing the 26 00:01:26,400 --> 00:01:29,559 Speaker 2: technology out of the university, and so our path since 27 00:01:29,600 --> 00:01:33,839 Speaker 2: then has been to transform the technology essentially from working 28 00:01:33,840 --> 00:01:36,760 Speaker 2: in small models in mice through to scaling it to 29 00:01:37,000 --> 00:01:40,000 Speaker 2: larger animal models and then into humans for clinical studies. 30 00:01:40,280 --> 00:01:43,400 Speaker 2: So this you know in biotech. I say that when 31 00:01:43,400 --> 00:01:45,440 Speaker 2: you're doing development and biotech you wish you were own 32 00:01:45,480 --> 00:01:49,200 Speaker 2: information technology. Because we're about fourteen years into the process 33 00:01:49,200 --> 00:01:50,880 Speaker 2: so far, and we've invested about a quarter of a 34 00:01:50,880 --> 00:01:53,400 Speaker 2: billion dollars to get to the current point. But we've 35 00:01:53,440 --> 00:01:56,480 Speaker 2: now done a whole series of in fact five completed 36 00:01:56,520 --> 00:01:58,800 Speaker 2: phase one studies more than five hundred people. So we 37 00:01:58,840 --> 00:02:02,400 Speaker 2: know the technology works and you know I can describe 38 00:02:02,400 --> 00:02:04,080 Speaker 2: it to you in a nutshell if you're ready. 39 00:02:03,960 --> 00:02:08,440 Speaker 1: Yp please please describe the technology in English, David, in English, in. 40 00:02:08,440 --> 00:02:11,800 Speaker 2: English, in English, Well, it's well it's a fun space 41 00:02:11,840 --> 00:02:14,320 Speaker 2: to work in, first of all, because you know, we're 42 00:02:14,360 --> 00:02:17,560 Speaker 2: working in a field that really hasn't seen fundamental innovation 43 00:02:17,680 --> 00:02:19,440 Speaker 2: for more than one hundred and seventy years. I mean, 44 00:02:19,480 --> 00:02:21,880 Speaker 2: the needle and syringe is what we used to inject 45 00:02:22,320 --> 00:02:25,360 Speaker 2: vaccines because we have a needle. What we know, based 46 00:02:25,360 --> 00:02:27,840 Speaker 2: on modern immunology, is that the immune cells are actually 47 00:02:27,840 --> 00:02:30,280 Speaker 2: not in the muscle. Most of the immune cells in 48 00:02:30,320 --> 00:02:32,120 Speaker 2: your body are in fact in the surfaces, so in 49 00:02:32,120 --> 00:02:35,000 Speaker 2: the skin, your cosal surfaces, where you have about ten 50 00:02:35,040 --> 00:02:37,680 Speaker 2: thousand times in the density of immune cells. And so 51 00:02:37,919 --> 00:02:41,280 Speaker 2: we've developed technology that instead of injecting vaccine into muscle, 52 00:02:41,919 --> 00:02:44,640 Speaker 2: enables us to apply a small patch to the skin 53 00:02:44,680 --> 00:02:47,600 Speaker 2: for about ten seconds and we deposit the vaccine just 54 00:02:47,760 --> 00:02:51,120 Speaker 2: underneath the surface of the skin, basically into the arms 55 00:02:51,200 --> 00:02:54,440 Speaker 2: of the weighting immune cells. And that way they are 56 00:02:54,440 --> 00:02:57,400 Speaker 2: able to very efficiently pick up the vaccine and it's 57 00:02:57,400 --> 00:03:00,520 Speaker 2: still processed, you know, immunologically in the same way by 58 00:03:00,520 --> 00:03:03,160 Speaker 2: the lymph nodes, et cetera. But what it means is 59 00:03:03,160 --> 00:03:06,320 Speaker 2: that we have a dramatically more efficient and effective way 60 00:03:06,360 --> 00:03:09,280 Speaker 2: of getting a response to a vaccine, and that that's 61 00:03:09,360 --> 00:03:10,680 Speaker 2: just the start of good things. 62 00:03:11,440 --> 00:03:13,480 Speaker 1: Is it applicable to all vaccines? 63 00:03:14,000 --> 00:03:16,679 Speaker 2: It is, so, you know, in the broader sense, you 64 00:03:16,680 --> 00:03:19,600 Speaker 2: could say this is a potential replacement to needle and 65 00:03:19,639 --> 00:03:23,160 Speaker 2: syringe for all vaccinations. Now, of course, for those of 66 00:03:23,200 --> 00:03:27,040 Speaker 2: us who who like needles, I can ensure you've done 67 00:03:27,080 --> 00:03:30,040 Speaker 2: the research, and it's a pretty small population, it doesn't 68 00:03:30,040 --> 00:03:32,480 Speaker 2: make much difference. But there is actually in the field 69 00:03:32,520 --> 00:03:34,920 Speaker 2: of vaccines, there is a lot of because vaccines are optional. 70 00:03:34,960 --> 00:03:37,640 Speaker 2: I mean that when you're getting a therapeutic injection, you 71 00:03:37,680 --> 00:03:40,560 Speaker 2: want it because you're sick. You're getting vaccines because you're 72 00:03:40,600 --> 00:03:43,520 Speaker 2: healthy and when you're healthy, and that's so it's a choice. 73 00:03:43,840 --> 00:03:47,040 Speaker 2: And you know, apprehension or anxiety around needles is actually 74 00:03:47,080 --> 00:03:49,160 Speaker 2: one of the real barriers to it. So a technology 75 00:03:49,200 --> 00:03:52,040 Speaker 2: like ours can lift that veil completely, and there are 76 00:03:52,080 --> 00:03:54,800 Speaker 2: other advantages. The way we put the vaccine onto the 77 00:03:55,240 --> 00:03:58,600 Speaker 2: of the patch, it's dry, so it can be stored 78 00:03:58,600 --> 00:04:01,440 Speaker 2: outside of refrigeration, and that this means for things like 79 00:04:01,480 --> 00:04:04,760 Speaker 2: our seasonal flu vaccine can be stable at forty degree 80 00:04:04,840 --> 00:04:07,200 Speaker 2: centigrade for more than a year. I was opposed to 81 00:04:07,240 --> 00:04:10,680 Speaker 2: having to have this kind of tightly controlled refrigeration distribution, 82 00:04:11,160 --> 00:04:13,120 Speaker 2: so You know, we have two ways that we look 83 00:04:13,120 --> 00:04:15,240 Speaker 2: at the world. You know, one, in the high income 84 00:04:15,280 --> 00:04:18,160 Speaker 2: countries where we have the benefits of things like refrigeration 85 00:04:18,760 --> 00:04:22,360 Speaker 2: and skilled administration, we take vaccines for branded. But most 86 00:04:22,400 --> 00:04:25,080 Speaker 2: of the world's population we were with there's poor infrastructure 87 00:04:25,160 --> 00:04:28,920 Speaker 2: and not much skilled administration healthcare. Where we can extend 88 00:04:28,920 --> 00:04:31,200 Speaker 2: the reach of vaccines into places that are difficult or 89 00:04:31,240 --> 00:04:34,000 Speaker 2: impossible to reach with vaccines, and that that can be 90 00:04:34,000 --> 00:04:34,920 Speaker 2: a real game changer. 91 00:04:35,520 --> 00:04:38,440 Speaker 1: You talked about the trials, I mean, starting with mice 92 00:04:38,640 --> 00:04:42,600 Speaker 1: and going through to humans. Again, one thing that amazes 93 00:04:42,640 --> 00:04:46,160 Speaker 1: me when you read about these clinical trials, just like 94 00:04:46,279 --> 00:04:49,039 Speaker 1: how it's discovered. You know, who came up with the idea, 95 00:04:49,480 --> 00:04:52,400 Speaker 1: how do you actually migrate that to trialing it on 96 00:04:52,560 --> 00:04:54,920 Speaker 1: mice to trialing it in humans? Right? 97 00:04:55,440 --> 00:04:58,920 Speaker 2: That process, right, that's the kind of the seed of innovation. 98 00:04:58,960 --> 00:05:03,400 Speaker 2: You're right, because folks have actually known for many decades 99 00:05:03,480 --> 00:05:05,640 Speaker 2: that the immune cells are actually these classes of immune 100 00:05:05,640 --> 00:05:06,960 Speaker 2: cells are in the skin. If you really want to 101 00:05:07,000 --> 00:05:10,440 Speaker 2: put vaccine somewhere, that's the place to do it. There 102 00:05:10,520 --> 00:05:13,240 Speaker 2: was a technique developed to use a needle, which requires 103 00:05:13,279 --> 00:05:15,120 Speaker 2: the needle to be kind of put obliqually into the 104 00:05:15,160 --> 00:05:17,240 Speaker 2: skin and in certainly the way that you really don't 105 00:05:17,240 --> 00:05:20,920 Speaker 2: want to imagine getting vaccinated that way. And so it's 106 00:05:21,000 --> 00:05:23,880 Speaker 2: really then taking the knowledge that you know that's where 107 00:05:23,880 --> 00:05:26,919 Speaker 2: the immune cells are and then reducing to practice a 108 00:05:26,920 --> 00:05:29,440 Speaker 2: device that can achieve that. And that's what the University 109 00:05:29,480 --> 00:05:32,120 Speaker 2: of Queensland and it was Professor Mark Kendall at the 110 00:05:32,160 --> 00:05:35,880 Speaker 2: AIBN who came up with that original innovation. Essentially a 111 00:05:35,920 --> 00:05:38,200 Speaker 2: controlled way to place the vaccine right where those immune 112 00:05:38,200 --> 00:05:41,800 Speaker 2: cells are. Now from going into a demonstrating you get 113 00:05:41,920 --> 00:05:44,440 Speaker 2: a response. You know, in mice is one thing. When 114 00:05:44,480 --> 00:05:47,920 Speaker 2: you want to take the technology into humans, it's a 115 00:05:47,960 --> 00:05:51,040 Speaker 2: completely different thing. You have to work out how it's 116 00:05:51,080 --> 00:05:53,279 Speaker 2: a medical device that we make that contains the patch 117 00:05:53,360 --> 00:05:56,279 Speaker 2: that is coated with vaccine. So it is a product 118 00:05:56,279 --> 00:05:58,680 Speaker 2: that needs to be made in a sterile environment and 119 00:05:58,720 --> 00:06:02,800 Speaker 2: our facility at Holton Northshaw we have clean rooms and 120 00:06:02,800 --> 00:06:05,640 Speaker 2: that we have highly skilled operators that enable us to 121 00:06:05,680 --> 00:06:08,880 Speaker 2: tape the sterilized components of the device applied to vaccine 122 00:06:08,880 --> 00:06:11,920 Speaker 2: in a sterile environment and seal it and then it's 123 00:06:11,960 --> 00:06:14,640 Speaker 2: refused then in human clinical trials. And I said, we've 124 00:06:14,640 --> 00:06:18,120 Speaker 2: become very skilled at this We've completed five really successful 125 00:06:18,160 --> 00:06:22,719 Speaker 2: Phase one studies. Today we're just completing a very large 126 00:06:22,760 --> 00:06:25,440 Speaker 2: study for the US government about two hundred and sixty people. 127 00:06:25,640 --> 00:06:29,120 Speaker 2: I'm using actually a pre pandemic influenza vaccine from the 128 00:06:29,200 --> 00:06:33,040 Speaker 2: US stockpile, and so we've become super skilled in how 129 00:06:33,080 --> 00:06:35,560 Speaker 2: to produce great material for clinical studies and that's the 130 00:06:35,600 --> 00:06:37,839 Speaker 2: stepping stone to the commercial market. 131 00:06:38,279 --> 00:06:44,160 Speaker 1: Say with me, David. We'll be back in a minute. 132 00:06:47,160 --> 00:06:50,240 Speaker 1: My guest this morning is David Howey, President and CEO 133 00:06:50,440 --> 00:06:54,159 Speaker 1: of Vaxus. Before the break, you kind of gave us 134 00:06:54,160 --> 00:06:57,040 Speaker 1: a rundown of how we got to where we are today. 135 00:06:57,560 --> 00:06:59,919 Speaker 1: What's the size of the prize here, David? 136 00:07:00,880 --> 00:07:03,560 Speaker 2: The size of the pre is very large. The global 137 00:07:03,880 --> 00:07:06,200 Speaker 2: vaccine market is about one hundred and thirty billion, and 138 00:07:06,279 --> 00:07:09,640 Speaker 2: as we discussed earlier, the technology itself is you could 139 00:07:09,640 --> 00:07:12,400 Speaker 2: think of it essentially as a replacement for needland syrenge. 140 00:07:12,400 --> 00:07:14,840 Speaker 2: So there is not an existing vaccine or a vaccine 141 00:07:14,840 --> 00:07:17,920 Speaker 2: in development. This is not applicable too. So we see 142 00:07:17,920 --> 00:07:21,440 Speaker 2: ourselves as being able to enter many of the disease 143 00:07:21,440 --> 00:07:24,320 Speaker 2: segments that are currently occupied by needle and syringe and 144 00:07:24,360 --> 00:07:27,440 Speaker 2: simply garnering market share. Because we know we have very 145 00:07:27,440 --> 00:07:30,400 Speaker 2: strong consumer preference, but there are also vaccines that are 146 00:07:30,440 --> 00:07:34,400 Speaker 2: in development and that we can confer special properties if 147 00:07:34,440 --> 00:07:36,520 Speaker 2: you like, to those vaccines. We tend to generate a 148 00:07:36,560 --> 00:07:39,080 Speaker 2: faster and a higher immune response and that you know, 149 00:07:39,200 --> 00:07:41,200 Speaker 2: a different flavor of immune response and called it a 150 00:07:41,240 --> 00:07:44,280 Speaker 2: broader immune response to vaccines. So this can sort of 151 00:07:44,320 --> 00:07:46,440 Speaker 2: be transformative over time. I like to think if we 152 00:07:46,520 --> 00:07:48,880 Speaker 2: fast forward, you know, sort of twenty years from now, 153 00:07:49,280 --> 00:07:53,160 Speaker 2: most vaccines will be given by patch administration because that's 154 00:07:53,200 --> 00:07:55,120 Speaker 2: where the immune cells are, and that we hope that 155 00:07:55,240 --> 00:07:57,120 Speaker 2: most of those patches are outs. 156 00:07:57,480 --> 00:08:01,120 Speaker 1: So for your sake, they are too where how close 157 00:08:01,200 --> 00:08:03,760 Speaker 1: are we to roll it? Are you to rolling it out? 158 00:08:04,480 --> 00:08:09,120 Speaker 2: Very close? So the facility at Brisbane's North Shore, you know, 159 00:08:09,160 --> 00:08:12,440 Speaker 2: it's a bespoke facility and fantastic. We're about to start 160 00:08:12,480 --> 00:08:15,280 Speaker 2: producing material for our later stage studies, so phase two 161 00:08:15,280 --> 00:08:18,480 Speaker 2: and phase three and then our first commercial products. We're 162 00:08:18,480 --> 00:08:20,800 Speaker 2: somewhere between three and five years out, and if the 163 00:08:20,840 --> 00:08:23,960 Speaker 2: trials go smoothly, maybe twenty twenty eight for registration of 164 00:08:24,000 --> 00:08:26,000 Speaker 2: our first products, or a year or two after. But 165 00:08:26,360 --> 00:08:29,720 Speaker 2: in the biotech landscape, that's incredibly close. So it's very exciting. 166 00:08:30,520 --> 00:08:32,679 Speaker 1: You mentioned Brisbane a few times. It seems to have 167 00:08:32,920 --> 00:08:35,240 Speaker 1: be the place to be med take biotech take. I 168 00:08:35,240 --> 00:08:39,000 Speaker 1: mean there's a few listed companies here Technology One for example, 169 00:08:39,000 --> 00:08:41,880 Speaker 1: Brisbane based company that's that everyone loves Technology one at 170 00:08:41,920 --> 00:08:43,600 Speaker 1: the moment, but it just seems to be the place 171 00:08:43,640 --> 00:08:44,160 Speaker 1: at the moment. 172 00:08:44,360 --> 00:08:47,280 Speaker 2: Yeah, it's a fantastic place you know, to first of all, 173 00:08:47,320 --> 00:08:49,560 Speaker 2: you know, incubate and then in our case, if you 174 00:08:49,600 --> 00:08:52,120 Speaker 2: take it from a concept to a company that in 175 00:08:52,120 --> 00:08:56,480 Speaker 2: twenty eleven had six people and has since then raised 176 00:08:56,480 --> 00:08:59,240 Speaker 2: one hundred million dollars or so in conventional venture finance 177 00:08:59,280 --> 00:09:01,600 Speaker 2: and one hundred others hundred and eighty million in NONOLU 178 00:09:01,720 --> 00:09:05,520 Speaker 2: funding for folks like the US government pharmaceutical companies. We're 179 00:09:05,520 --> 00:09:08,160 Speaker 2: now about one hundred and seventy people, and that most 180 00:09:08,160 --> 00:09:10,160 Speaker 2: of the investment, about a quarter of a billion so 181 00:09:10,280 --> 00:09:13,000 Speaker 2: far is spent locally into the local economy. And so 182 00:09:13,040 --> 00:09:17,120 Speaker 2: we're part of this growing biotech colonel an ecosystem that 183 00:09:17,280 --> 00:09:19,640 Speaker 2: is fantastic because we've sort of ridden away with a 184 00:09:19,640 --> 00:09:22,120 Speaker 2: lot of other companies. We've got the big ones of 185 00:09:22,120 --> 00:09:24,320 Speaker 2: course that we look at and what to emulate. It's 186 00:09:24,320 --> 00:09:26,959 Speaker 2: like cookpor Cochlear, et cetera. That are you know, already 187 00:09:26,960 --> 00:09:29,520 Speaker 2: famous that we say, but we're part of our growing 188 00:09:29,559 --> 00:09:31,520 Speaker 2: community and the more of us, the figure to be 189 00:09:31,559 --> 00:09:35,280 Speaker 2: the snowball gets bigger, and you know it's it's fantastic 190 00:09:35,320 --> 00:09:39,000 Speaker 2: too because institutions like the University of Queensland churn out 191 00:09:39,600 --> 00:09:42,520 Speaker 2: highly skilled scientists and engineers that are our target hiring 192 00:09:42,559 --> 00:09:45,640 Speaker 2: base and so we're a great recruitment tool keep those 193 00:09:45,679 --> 00:09:50,400 Speaker 2: people local and continue to feedback into the system. And 194 00:09:50,920 --> 00:09:54,439 Speaker 2: Brisbane is a great climate in more ways than one. Economically, 195 00:09:55,040 --> 00:09:57,520 Speaker 2: literally to recruit people to come here, even from overseas 196 00:09:57,720 --> 00:10:01,040 Speaker 2: is very very easy, and so we're super excited about 197 00:10:01,520 --> 00:10:04,120 Speaker 2: what we've been able to achieve locally, but also what 198 00:10:04,240 --> 00:10:05,920 Speaker 2: the ecosystem has given back to us. 199 00:10:06,360 --> 00:10:08,280 Speaker 1: I mean, there is that sense of paying forward, like 200 00:10:08,480 --> 00:10:11,199 Speaker 1: kind of fostering the next generation of healthcare startups because 201 00:10:11,240 --> 00:10:12,439 Speaker 1: you guys do that, don't you. 202 00:10:12,520 --> 00:10:15,200 Speaker 2: We do. We're actively involved in the mentoring programs that 203 00:10:15,240 --> 00:10:19,120 Speaker 2: BEIDA organizes, one of the many activities that be to 204 00:10:19,120 --> 00:10:22,120 Speaker 2: do to sort of foster you know, big biotech companies 205 00:10:22,120 --> 00:10:24,600 Speaker 2: start as small biotech companies, which start as an idea, 206 00:10:24,840 --> 00:10:27,200 Speaker 2: and that BEIDA have got sort of the from the 207 00:10:27,240 --> 00:10:30,120 Speaker 2: from the kernel an idea through how do you nurture 208 00:10:30,720 --> 00:10:33,360 Speaker 2: these companies that are a concept. We do mentoring with 209 00:10:34,160 --> 00:10:38,160 Speaker 2: early stage companies. BEIDA also have active programs to introduce 210 00:10:38,679 --> 00:10:40,719 Speaker 2: companies when they're coming into the stage when they need 211 00:10:40,720 --> 00:10:43,440 Speaker 2: to raise their first capital, not just to the Australian community, 212 00:10:43,480 --> 00:10:46,760 Speaker 2: but to international audiences, particularly you know in the US 213 00:10:46,760 --> 00:10:49,880 Speaker 2: the big biotech conferences here at GP Morgan, etcetera. Bidda 214 00:10:49,920 --> 00:10:52,880 Speaker 2: have done a phenomenal job. We by the way, participate 215 00:10:52,920 --> 00:10:55,880 Speaker 2: in those programs so we benefit from them, but we 216 00:10:55,960 --> 00:10:59,959 Speaker 2: also help other companies to participate across. 217 00:10:59,720 --> 00:11:02,440 Speaker 1: The rain tour round it off, David, what next for Vaxis? 218 00:11:02,440 --> 00:11:04,079 Speaker 1: So what do we expect for the next five years? 219 00:11:04,800 --> 00:11:07,360 Speaker 2: Five years? Oh boy, there's lots of things going on, 220 00:11:07,679 --> 00:11:10,200 Speaker 2: you know. Well. Out at our facility at north Shore, 221 00:11:10,320 --> 00:11:13,679 Speaker 2: we're installing our first rebute systems for manufacturing, which is 222 00:11:13,720 --> 00:11:16,360 Speaker 2: a really exciting transition time. We're gearing up for our 223 00:11:16,400 --> 00:11:19,680 Speaker 2: first midstage so phase two and phase three studies. We're 224 00:11:19,720 --> 00:11:22,439 Speaker 2: engaging with lots of government entities, not just the US 225 00:11:22,520 --> 00:11:26,840 Speaker 2: government and farmer so exciting. Our new vaccine programs no 226 00:11:26,840 --> 00:11:28,240 Speaker 2: a heck of a lot going on, and of course, 227 00:11:28,480 --> 00:11:31,040 Speaker 2: most importantly the launch of our first products really exciting. 228 00:11:31,559 --> 00:11:33,199 Speaker 1: David, thank you for talking to Fear and Greed. 229 00:11:33,440 --> 00:11:34,720 Speaker 2: Great thanks very out Sean. 230 00:11:34,800 --> 00:11:37,440 Speaker 1: That is David Howey, President and CEO of Vaxis, which 231 00:11:37,480 --> 00:11:40,920 Speaker 1: works with the Brisbane Economic Development Agency. David was talking 232 00:11:40,960 --> 00:11:43,920 Speaker 1: about BETA. That's it Brisbane Economic Development. That agency a 233 00:11:43,920 --> 00:11:46,080 Speaker 1: great supporter of this podcast. This is the Fear and 234 00:11:46,120 --> 00:11:48,840 Speaker 1: Greed Business Interview. Join us every morning for the full 235 00:11:48,880 --> 00:11:51,679 Speaker 1: episode of Fear and Greed at Business News. You can 236 00:11:51,800 --> 00:11:55,439 Speaker 1: use I'm Sean Elmer. Enjoy your day.